Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8901308 | 0.87 | MAPK1 (0.49) | PTPN11 | |
| SCHEMBL6196393 | 0.86 | PTPN11 (0.57) | AKR1C3AKR1C2CREBBPPTPN11HDAC1 | |
| SCHEMBL6200527 | 0.85 | PTPN11 (0.63) | AKR1C3AKR1C2CREBBPPTPN11HDAC1 | |
| SCHEMBL5050751 | 0.84 | KMT2A (0.55) | CREBBP | |
| SCHEMBL7568390 | 0.84 | PTPN11 (0.51) | AKR1C3AKR1C2CREBBPPTPN11 | |
| SCHEMBL641868 | 0.83 | CREBBP (0.64) | AKR1C3AKR1C2CREBBPHDAC1HDAC8 | |
| SCHEMBL7566116 | 0.81 | PTGDR2 (0.63) | AKR1C3AKR1C2CREBBPAKR1B10AKR1B1 | |
| SCHEMBL13528549 | 0.81 | AKR1C3 (0.51) | AKR1C3AKR1C2CREBBPPTPN11AKR1B10 | |
| SCHEMBL1505121 | 0.81 | KDM4E (0.52) | PTPN11 | |
| SCHEMBL1505305 | 0.81 | PTGDR2 (0.55) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | AKR1C3 97/4885AKR1C2 246/4885CREBBP 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.